Aliases & Classifications for Alopecia

Summaries for Alopecia

Disease Ontology : 12 A hypotrichosis that is characterized by a loss of hair from the head or body.

MalaCards based summary : Alopecia is related to alopecia universalis congenita and androgenic alopecia, and has symptoms including pruritus and exanthema. An important gene associated with Alopecia is HR (HR, Lysine Demethylase And Nuclear Receptor Corepressor). The drugs Clobetasol and Acitretin have been mentioned in the context of this disorder. Affiliated tissues include Hair and Hair, and related phenotypes are Mildly decreased CFP-tsO45G cell surface transport and growth/size/body region

Wikipedia : 72 Hair loss, also known as alopecia or baldness, refers to a loss of hair from part of the head or body.... more...

Related Diseases for Alopecia

Diseases in the Alopecia family:

Alopecia, Congenital

Diseases related to Alopecia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 526)
# Related Disease Score Top Affiliating Genes
1 alopecia universalis congenita 33.9 AIRE FOXN1 HR MBTPS2
2 androgenic alopecia 33.0 AR EDA2R HR
3 clouston syndrome 32.0 ANTXR1 GJA1 TP63
4 nail disorder, nonsyndromic congenital, 1 31.8 AIRE MBTPS2 TP63
5 hypohidrosis 29.6 KRT14 TP63
6 hypotrichosis 29.5 DCAF17 GJA1 HR KRT86
7 alopecia areata 12.5
8 alopecia, androgenetic, 1 12.4
9 alopecia totalis 12.3
10 frontal fibrosing alopecia 12.3
11 alopecia, neurologic defects, and endocrinopathy syndrome 12.2
12 mandibulofacial dysostosis with alopecia 12.2
13 t-cell immunodeficiency, congenital alopecia, and nail dystrophy 12.2
14 central centrifugal cicatricial alopecia 12.2
15 palmoplantar keratoderma and congenital alopecia 2 12.2
16 polyposis, skin pigmentation, alopecia, and fingernail changes 12.1
17 diffuse alopecia areata 12.1
18 palmoplantar keratoderma and congenital alopecia 1 12.1
19 alopecia-contractures-dwarfism mental retardation syndrome 12.1
20 ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis 12.1
21 alopecia-mental retardation syndrome 1 12.1
22 alopecia, epilepsy, pyorrhea, mental subnormality 12.0
23 autosomal recessive palmoplantar keratoderma and congenital alopecia 12.0
24 alopecia-intellectual disability syndrome 12.0
25 odonto onycho dysplasia with alopecia 12.0
26 alopecia areata 1 12.0
27 alopecia, congenital 12.0
28 ichthyosis alopecia eclabion ectropion mental retardation 12.0
29 autosomal dominant palmoplantar keratoderma and congenital alopecia 11.9
30 alopecia universalis onychodystrophy vitiligo 11.9
31 alopecia-contractures-dwarfism-intellectual disability syndrome 11.9
32 alopecia-epilepsy-oligophrenia syndrome of moynahan 11.9
33 woodhouse-sakati syndrome 11.8
34 alopecia universalis congenita, xy gonadal dysgenesis, and laryngomalacia 11.8
35 gapo syndrome 11.8
36 lichen planopilaris 11.8
37 alopecia, psychomotor epilepsy, pyorrhea, and mental subnormality 11.8
38 thumb deformity and alopecia 11.8
39 hypergonadotropic hypogonadism and partial alopecia 11.8
40 alopecia, androgenetic, 2 11.8
41 alopecia-mental retardation syndrome 2 11.8
42 alopecia areata 2 11.8
43 alopecia, androgenetic, 3 11.8
44 alopecia-mental retardation syndrome 3 11.8
45 alopecia intellectual disability syndrome 2 11.8
46 frontonasal dysplasia with alopecia and genital anomaly 11.8
47 alopecia, familial focal 11.7
48 ichthyosis with alopecia, eclabium, ectropion, and mental retardation 11.7
49 alopecia-mental retardation syndrome with convulsions and hypergonadotropic hypogonadism 11.7
50 ectodermal dysplasia alopecia preaxial polydactyly 11.7

Graphical network of the top 20 diseases related to Alopecia:



Diseases related to Alopecia

Symptoms & Phenotypes for Alopecia

UMLS symptoms related to Alopecia:


pruritus, exanthema

GenomeRNAi Phenotypes related to Alopecia according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Mildly decreased CFP-tsO45G cell surface transport GR00360-A-1 9.4 AIRE ANTXR1 AR DCAF17 DSP EDNRA

MGI Mouse Phenotypes related to Alopecia:

43 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.32 FOXN1 AIRE AUTS2 DSP ANTXR1 EDNRA
2 cardiovascular system MP:0005385 10.29 AR FOXN1 DSP ANTXR1 EDNRA VDR
3 cellular MP:0005384 10.28 EDNRA AR DSP ANTXR1 VDR SLC39A4
4 endocrine/exocrine gland MP:0005379 10.24 AR FOXN1 AIRE ANTXR1 EDNRA VDR
5 craniofacial MP:0005382 10.22 DSP ANTXR1 EDNRA AR TP63 VDR
6 digestive/alimentary MP:0005381 10.16 AR AIRE DSP EDNRA VDR TP63
7 mortality/aging MP:0010768 10.15 EDNRA AR AIRE DSP ANTXR1 VDR
8 immune system MP:0005387 10.13 EDNRA AR AIRE ANTXR1 VDR TP63
9 integument MP:0010771 10.06 AR DSP EDNRA VDR TP63 HR
10 hearing/vestibular/ear MP:0005377 9.93 EDNRA VDR GJA1 KRT14 HR FOXN1
11 muscle MP:0005369 9.92 AR DSP EDNRA VDR SLC39A4 TP63
12 reproductive system MP:0005389 9.81 AR AIRE ANTXR1 VDR TP63 HR
13 neoplasm MP:0002006 9.8 AR AIRE ANTXR1 TP63 HR FOXN1
14 skeleton MP:0005390 9.61 AR ANTXR1 EDNRA VDR SLC39A4 TP63
15 vision/eye MP:0005391 9.28 AIRE EDNRA SLC39A4 TP63 HR FOXN1

Drugs & Therapeutics for Alopecia

Drugs for Alopecia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 372)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clobetasol Approved, Investigational Phase 4,Phase 3 25122-41-2, 25122-46-7 5311051 32798
2
Acitretin Approved Phase 4 55079-83-9 5284513 6437841
3
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
4
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
5
Triamcinolone Approved, Vet_approved Phase 4,Phase 2 124-94-7 31307
6
Finasteride Approved Phase 4,Phase 3,Phase 1,Phase 2 98319-26-7 57363
7
Minoxidil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 38304-91-5 4201
8
Imiquimod Approved, Investigational Phase 4,Phase 3 99011-02-6 57469
9
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
10
Latanoprost Approved, Investigational Phase 4 130209-82-4 5311221 5282380
11
Hydroxychloroquine Approved Phase 4 118-42-3 3652
12
Capsaicin Approved Phase 4 404-86-4 1548943
13
Bimatoprost Approved, Investigational Phase 4,Phase 2,Phase 1 155206-00-1 5311027
14
Doxorubicin Approved, Investigational Phase 4,Phase 2,Phase 3 23214-92-8 31703
15
Drospirenone Approved Phase 4 67392-87-4 68873
16
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
17
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
18
Hydroxocobalamin Approved Phase 4 13422-51-0 5460373 44475014 11953898
19
Spironolactone Approved Phase 4,Phase 2 1952-01-7, 52-01-7 5833
20
Apremilast Approved, Investigational Phase 4,Phase 2 608141-41-9 11561674
21
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
22
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 143 6006
23 Orange Approved, Nutraceutical Phase 4
24
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
25
Manganese Approved, Nutraceutical Phase 4 7439-96-5 27854
26
Methylcobalamin Approved, Experimental, Investigational, Nutraceutical Phase 4 13422-55-4
27
Doxil Approved June 1999 Phase 4,Phase 2,Phase 3 31703
28 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
29 Dermatologic Agents Phase 4,Phase 3,Phase 1,Phase 2
30 Emollients Phase 4
31 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
32 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2
33 Hormones Phase 4,Phase 3,Phase 1,Phase 2
34 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2
35 Keratolytic Agents Phase 4
36 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1
37 Anti-Asthmatic Agents Phase 4,Phase 1,Phase 2
38 Antihypertensive Agents Phase 4,Phase 3,Phase 1,Phase 2
39 Respiratory System Agents Phase 4,Phase 1,Phase 2
40 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
41 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Antiemetics Phase 4,Phase 2,Phase 1
43 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
44 Autonomic Agents Phase 4,Phase 1,Phase 2
45 Gastrointestinal Agents Phase 4,Phase 2,Phase 1
46 Methylprednisolone acetate Phase 4
47 Methylprednisolone Hemisuccinate Phase 4
48 Neuroprotective Agents Phase 4,Phase 2
49 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
50 Prednisolone acetate Phase 4

Interventional clinical trials:

(show top 50) (show all 338)

# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in Alopecia Unknown status NCT01111981 Phase 4 Clobetasol Propionate 0.05% Emollient Foam
2 Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects? Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
3 Aldara for the Treatment of Extensive Alopecia Areata Completed NCT00177021 Phase 4 Aldara Cream 5%
4 Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Treatment With Aldara 5% Completed NCT00176943 Phase 4 Aldara Cream 5%
5 Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata Completed NCT02350023 Phase 4 Topical latanoprost 0.005%;Topical betamethasone 0.05%
6 Plaquenil for Alopecia Areata, Alopecia Totalis Completed NCT00176982 Phase 4 Hydroxychloroquine
7 Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata Completed NCT01167946 Phase 4 methylprednisolone sodium succinate;methylprednisolone sodium succinate;methylprednisolone sodium succinate
8 Response of Topical Capsaicin in Alopecia Areata Completed NCT00176969 Phase 4 Capsaicin
9 Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children Completed NCT01023841 Phase 4 bimatoprost ophthalmic solution 0.03%;Vehicle Sterile Solution
10 Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma Completed NCT00969462 Phase 4 Doxorubicin
11 Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin Resistance Completed NCT01511822 Phase 4 Drospirenone Ethinyl estradiol;Drospirenone Ethinyl estradiol Myo-inositol;placebo
12 Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses Completed NCT00774787 Phase 4 imiquimod 5% cream
13 Myo-inositol Versus D-chiro-inositol in the Treatment of Polycystic Ovary Syndrome and Insulin Resistance: Evaluation of Clinical, Metabolic, Endocrine and Ultrasound Parameters Completed NCT01514942 Phase 4 Folic acid, vit B12;Folic acid, vit B12
14 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents Completed NCT01424644 Phase 4
15 Intralesional Steroids in the Treatment of Alopecia Areata Recruiting NCT01898806 Phase 4 Intralesional Triamcinolone 2.5 mg/ml;Intralesional Triamcinolone 5 mg/ml;Intralesional Triamcinolone 10 mg/ml;Intralesional Saline
16 Adipose Derived Stem Cells Versus Platelet Rich Plasma on Follicular Unit Extraction Recruiting NCT03388840 Phase 4
17 Comparing Different Platelet Rich Plasma (PRP) Treatment Regimens for Management of Androgenic Alopecia Active, not recruiting NCT02999737 Phase 4
18 Trial Evaluating the Efficacy of Apremilast for the Treatment of Frontal Fibrosing Alopecia Not yet recruiting NCT03422640 Phase 4 Apremilast
19 The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia Withdrawn NCT02483195 Phase 4 5% Minoxidil;200mg Spironolactone;5mg Finasteride
20 Topical Garlic Concentrate for Alopecia Areata in Children Unknown status NCT02691117 Phase 3 garlic concentrate
21 Efficacy and Safety of Mesotherapy With Minoxidil 0.5%/2ml for Androgenetic Alopecia in Female Patients Unknown status NCT01655108 Phase 3 Minoxidil;Saline
22 Reflexology's Effect on Polycystic Ovary Syndrome: A Pilot Study Unknown status NCT00746148 Phase 3
23 Reflexology's Effect on Polycystic Ovary Syndrome (PCOS) Unknown status NCT00744510 Phase 3
24 Treatment of the Recessive Nonbullous Congenital Ichthyosis by the Epigallocatechine Cutaneous Unknown status NCT01222000 Phase 3 apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side;apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side
25 The Randomized Double-blind Placebo-controlled Trial of Intralesional Botulinum Toxin A Injection for Recalcitrant Alopecia Totalis and Alopecia Universalis Completed NCT00997815 Phase 2, Phase 3 Botulinum toxin A;Normal saline injection
26 Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata Completed NCT00063076 Phase 2, Phase 3 Targretin Gel 1%
27 A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia Completed NCT01831791 Phase 3 Dutasteride 0.5 mg
28 Efficacy and Safety Study to Compare Two Minoxidil Formulations on Women With Androgenetic Alopecia Completed NCT00958750 Phase 3 minoxidil
29 A Trial of Clobetasol Propionate Versus Hydrocortisone in Children With Alopecia Areata Completed NCT01453686 Phase 3 Hydrocortisone 1%;Clobetasol Propionate 0.05%
30 Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia Completed NCT02014584 Phase 3 Dutasteride;Placebo
31 A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6 Months In The Treatment Of Male Subjects With Androgenetic Alopecia Completed NCT00441116 Phase 3 Dutasteride 0.5mg oral tablets
32 Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia Completed NCT01231607 Phase 3 1mg Finasteride active;0.02mg dutasteride;0.1mg dutasteride;0.5mg dutasteride;Finasteride placebo;Dutasteride placebo
33 Clinical Trial in Females With Female Pattern Hair Loss Completed NCT01145625 Phase 3 5% Minoxidil;2% Minoxidil
34 A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss Completed NCT00151515 Phase 3 minoxidil
35 Clinical Trial in Females for Female Pattern Hair Loss Completed NCT01226459 Phase 3 5% Minoxidil Topical Foam;Vehicle Topical Foam
36 Enhancing Hair Density With Platelet Rich Fibrin Matrix (PRFM) Completed NCT01590238 Phase 3
37 Efficacy Study of Minoxidil Lotion Versus Combined Minoxidil and Finasteride Lotion to Treat Male Pattern Hair Loss Completed NCT01391156 Phase 3 3%Minoxidil lotion;3% Minoxidil with 0.1% Finasteride lotion
38 Effects of Finasteride on Serum Prostate-Specific Antigen (0906-111) Completed NCT00396175 Phase 3 MK0906, finasteride / Duration of Treatment : 48 Weeks;Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks
39 Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up Completed NCT02549352 Phase 3 LEO43204 gel;Vehicle gel
40 Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up Completed NCT02547363 Phase 3 LEO 43204 gel;Vehicle gel
41 A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp Completed NCT02611804 Phase 3 Diclofenac sodium;Diclofenac sodium;Placebo
42 Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis Completed NCT01686152 Phase 3 Imiquimod Cream, 3.75%;Zyclara®
43 Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest Completed NCT02361216 Phase 3 Ingenol Mebutate
44 Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (AKs) Completed NCT00603798 Phase 3 Imiquimod cream;Placebo cream;Imiquimod cream
45 Safety and Effectiveness Study of Imiquimod Creams for Treatment of Actinic Keratoses (AKs) Completed NCT00605176 Phase 3 imiquimod cream;imiquimod cream;Placebo
46 Terbinafine Compared to Griseofulvin in Children With Tinea Capitis Completed NCT00117767 Phase 3 Terbinafine hydrochloride (HCl);Griseofulvin
47 Terbinafine Compared to Griseofulvin in Children With Tinea Capitis Completed NCT00117754 Phase 3 Terbinafine hydrochloride
48 A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Subjects With Actinic Keratoses Completed NCT02120898 Phase 3 Imiquimod
49 Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer Completed NCT01426880 Phase 2, Phase 3 Carboplatin;background treatment
50 Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) Completed NCT00916409 Phase 3 Temozolomide

Search NIH Clinical Center for Alopecia

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: alopecia

Genetic Tests for Alopecia

Genetic tests related to Alopecia:

# Genetic test Affiliating Genes
1 Alopecia 28

Anatomical Context for Alopecia

MalaCards organs/tissues related to Alopecia:

38
Breast, Brain, Skin, Ovary, Testes, T Cells, Prostate
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Alopecia:
# Tissue Anatomical CompartmentCell Relevance
1 Hair Hair Follicle Fetal Hair Placode Cells Affected by disease
2 Hair Hair Follicle Fetal Matrix Cells Affected by disease
3 Hair Dermal Papilla Guard Dermal Papilla Cells Affected by disease
4 Hair Hair Follicle Primary Hair Placode Cells Affected by disease

Publications for Alopecia

Articles related to Alopecia:

(show top 50) (show all 2143)
# Title Authors Year
1
Facial Papules in Frontal Fibrosing Alopecia: Good Response to Isotretinoin. ( 29395031 )
2018
2
Lichen planopilaris and frontal fibrosing alopecia cannot be differentiated by histopathology. ( 29369400 )
2018
3
Low-level laser therapy for the treatment of androgenic alopecia: a review. ( 29270707 )
2018
4
Applying the Common Sense Model to predicting quality of life in alopecia areata: The role of illness perceptions and coping strategies. ( 29355049 )
2018
5
Oligosecretory Myeloma With Amyloidosis and Alopecia. ( 29399587 )
2018
6
Unusual progression of renal cell carcinoma with carcinomatosis peritoneii and Krukenberg tumour and alopecia with sunitinib therapy in young female. ( 29409504 )
2018
7
Alopecia Areata: The Clinical Situation. ( 29273111 )
2018
8
Big Data Reveal Insights into Alopecia Areata Comorbidities. ( 29273109 )
2018
9
Alopecia: the questions we need to answer. ( 29441547 )
2018
10
Frontal fibrosing alopecia and cutaneous comorbidities: A potential relationship with rosacea. ( 29447678 )
2018
11
Reply to: "Tofacitinib for the treatment of severe alopecia areata and variants". ( 29332724 )
2018
12
Comparison of the Efficacy of Homologous and Autologous Platelet-Rich Plasma (PRP) for Treating Androgenic Alopecia. ( 29101437 )
2018
13
Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia. ( 29443105 )
2018
14
Ultraviolet filters in hair-care products: a possible link with frontal fibrosing alopecia and lichen planopilaris. ( 28994172 )
2018
15
Frontal fibrosing alopecia after antiandrogen hormonal therapy in a male patient. ( 29377270 )
2018
16
Retrospective review of 18 British South Asian women with frontal fibrosing alopecia. ( 29384198 )
2018
17
Evaluation of Alopecia: A New Processing Technique Combining Vertical and Transverse Sections from a Single Scalp Biopsy Specimen. ( 29440851 )
2018
18
Topical Immunotherapy of Alopecia Areata: A Large Retrospective Study. ( 29442292 )
2018
19
Androgenic alopecia in a postmenopausal Sicilian baroness. ( 29103134 )
2018
20
Alopecia areata after dupilumab for atopic dermatitis. ( 29387767 )
2018
21
A Meta-analysis On Evidence Of Platelet-rich Plasma for Androgenetic Alopecia. ( 29440850 )
2018
22
A novel PLEC nonsense homozygous mutation (c.7159Ga88>a88T; p.Glu2387*) causes epidermolysis bullosa simplex with muscular dystrophy and diffuse alopecia: a case report. ( 29352809 )
2018
23
Annular Alopecia Areata: A Morphologically Rare Variant. ( 29440858 )
2018
24
An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch Type Alopecia Areata, Totalis and Universalis. ( 29452121 )
2018
25
Histopathology of facial papules in frontal fibrosing alopecia and therapeutic response to oral isotretinoin. ( 29332726 )
2018
26
Clinical and histopathological aspects of an alopecia syndrome in captive Andean bears (Tremarctos ornatus). ( 29388354 )
2018
27
Association of Uterine Leiomyomas With Central Centrifugal Cicatricial Alopecia. ( 29282458 )
2018
28
Hemorrhagic Ischemic Retinal Vasculitis and Alopecia Areata as a Manifestation of HLA-B27. ( 29304269 )
2018
29
Genetic analysis of interleukin 18 gene polymorphisms in alopecia areata. ( 29349811 )
2018
30
Alopecia areata is associated with impaired health-related quality of life: a survey of affected adults and children, and their families. ( 29425723 )
2018
31
Updated diagnostic criteria for frontal fibrosing alopecia. ( 29241802 )
2018
32
Development of Frontal Fibrosing Alopecia with a History of Alopecia Areata. ( 29440856 )
2018
33
Nail changes in alopecia areata: an update and review. ( 29318582 )
2018
34
Cytokine Targeted Therapeutics forA Alopecia Areata: Lessons fromA Atopic Dermatitis and OtherA Inflammatory Skin Diseases. ( 29273110 )
2018
35
Acknowledging the pseudo "fringe sign" in frontal fibrosing alopecia has diagnostic and prognostic implications. ( 29241801 )
2018
36
Three Cases of Radiation-induced Temporary Alopecia with Hair Microscopic Examination: "Coudability Hair" Might Not be Specific for Alopecia Areata. ( 29440860 )
2018
37
Prognosis, treatment, and disease outcomes in frontal fibrosing alopecia: A retrospective review of 92 cases. ( 29241787 )
2018
38
Differential proteomics of lesional vs. non-lesional biopsies revealed non-immune mechanisms of alopecia areata. ( 29323127 )
2018
39
Reply to: "Histopathology of facial papules in frontal fibrosing alopecia and therapeutic response to oral isotretinoin". ( 29332727 )
2018
40
Sarcoidosis Presenting as Frontal Fibrosing Alopecia: A Master Mimicker or a Coincidental Finding? ( 29293480 )
2018
41
Is there an association of ABO blood groups and Rhesus factor with alopecia areata? ( 29336112 )
2018
42
A hypothetical pathogenesis model for androgenic alopecia: clarifying the dihydrotestosterone paradox and rate-limiting recovery factors. ( 29407002 )
2018
43
Childhood alopecia areata-Data from the National Alopecia Areata Registry. ( 29334143 )
2018
44
Whorled Scarring Alopecia - The Only Adult Marker of Incontinentia Pigmenti. ( 29440854 )
2018
45
Experience with oral tofacitinib in 8 adolescent patients with alopecia universalis. ( 28325392 )
2017
46
Response Letter to "Contact Dermatitis Associated with Alopecia and Hyperpigmentation". ( 28884898 )
2017
47
Alopecia areata as a paraneoplastic syndrome of gastric cancer. ( 27990839 )
2017
48
Inflammatory features of frontal fibrosing alopecia. ( 28429464 )
2017
49
Yellow facial papules associated with frontal fibrosing alopecia: A distinct histologic pattern and response to isotretinoin. ( 28917459 )
2017
50
Clinical and Histopathological Findings of Frontal Fibrosing Alopecia-Associated Lichen Planus Pigmentosus. ( 28560214 )
2017

Variations for Alopecia

Expression for Alopecia

Search GEO for disease gene expression data for Alopecia.

Pathways for Alopecia

GO Terms for Alopecia

Cellular components related to Alopecia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fascia adherens GO:0005916 8.96 DSP GJA1
2 intermediate filament GO:0005882 8.92 DSP GJA1 KRT14 KRT86

Biological processes related to Alopecia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.91 AIRE AR AUTS2 FOXN1 TP63 VDR
2 animal organ morphogenesis GO:0009887 9.54 FOXN1 TP63 VDR
3 cornification GO:0070268 9.5 DSP KRT14 KRT86
4 decidualization GO:0046697 9.4 GJA1 VDR
5 keratinocyte differentiation GO:0030216 9.33 DSP FOXN1 TP63
6 prostate gland development GO:0030850 9.26 AR TP63
7 epidermis development GO:0008544 9.02 DSP EDA2R FOXN1 KRT14 TP63
8 thymus epithelium morphogenesis GO:0097536 8.96 AIRE FOXN1

Sources for Alopecia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....